Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 10, 2012, Pages 5224-5229

  Villano, Stephen A ^a   Seiberling, Michael ^b   Tatarowicz, Walter ^a   Monnot Chase, Elizabeth ^a   Gerding, Dale N ^c,d  

^a ViroPharma Incorporated   (United States)

^b Covance Clinical Research Unit AG ^*  (Switzerland)

^c HINES VA HOSPITAL   (United States)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROBIOTIC AGENT; UNCLASSIFIED DRUG; VANCOMYCIN; VP 20621;

ABDOMINAL PAIN; ADULT; ANTICIPATORY NAUSEA AND VOMITING; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL SPORE; BACTERIUM CULTURE; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ERUPTION; DRUG SAFETY; ERYTHEMA; FECES ANALYSIS; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GINGIVA BLEEDING; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; ORAL PARESTHESIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TOOTH PAIN;

ADOLESCENT; ADULT; CLOSTRIDIUM DIFFICILE; DOUBLE-BLIND METHOD; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; MALE; MIDDLE AGED; SPORES, BACTERIAL; VANCOMYCIN; YOUNG ADULT;

EID: 84866313203     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00913-12     Document Type: Article

References (15)

1. Cadnum J, et al. 2011. Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment with oral vancomycin, abstr. 409. Abstr. Soc. Healthcare Epidemiol. Am. Annu. Scientific Meeting, Dallas, TX.
2. Clabots CR, et al. 1993. Development of a rapid and efficient restriction endonuclease analysis typing system for Clostridium difficile and correlation with other typing systems. J. Clin. Microbiol. 31:1870-1875. (Pubitemid 23182592)
3. Borriello SP, Barclay FE. 1985. Protection of hamsters against Clostridiumdifficile ileocaecitis by prior colonisation with non-pathogenic strains. J. Med. Microbiol. 19:339-350. (Pubitemid 15027247)
4. Finegold SM, et al. 1987. Bowel flora changes in humans receiving cefixime (CL 284,635) or cefaclor. Antimicrob. Agents Chemother. 31:443-446. (Pubitemid 17027136)
5. Iwata S, et al. 1991. The influence of cefpirome on intestinal bacterial flora. Jpn. J. Antibiot. 44:62-83.
6. Kyne L, Warny M, Qamar A, Kelly CP. 2001. Association between antibody response to toxin A and protection against recurrent Clostridiumdifficile diarrhoea. Lancet 357:189-193. (Pubitemid 32108091)
7. Kyne L, Warny M, Qamar A, Kelly CP. 2000. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 342:390-397. (Pubitemid 30084537)
8. Merrigan MM, Sambol SP, Johnson S, Gerding DN. 2003. Prevention of fatal Clostridium-difficile-associated disease during continuous administration of clindamycin in hamsters. J. Infect. Dis. 188:1922-1927. (Pubitemid 38064879)
9. Motohiro T, et al. 1986. Effect of cefminox on bacterial flora in human adult feces. Jpn. J. Antibiot. 39:909-957. (Pubitemid 16081777)
10. Sambol SP, Merrigan MM, Tang JK, Johnson S, Gerding DN. 2002. Colonization for the prevention of Clostridium difficile disease in hamsters. J. Infect. Dis. 186:1781-1789. (Pubitemid 35463511)
11. Seal D, et al. 1987. Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain. Eur. J. Clin. Microbiol. 6:51-53. (Pubitemid 17034620)
12. Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding DN. 1998. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 351:633-636. (Pubitemid 28098446)
13. Tatarowicz W, et al. Safety and tolerability of an oral suspension of VP20621, spores of a non-toxigenic C. difficile strain; first in human administration to healthy adult subjects, abstr. PIII-17. Abstr. 10th Biennial Congr. Anaerobe Soc. Am.
14. Villano SA, et al. 2010. Phase I evaluation of an oral suspension of VP20621, spores of a non-toxigenic C. difficile strain (NTCD), in healthy older subjects pretreated with vancomycin, abstr. F1-2127b. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
15. Wilson KH, Sheagren JN. 1983. Antagonism of toxigenic Clostridiumdifficile by nontoxigenic C. difficile. J. Infect. Dis. 147:733-736. (Pubitemid 13088248)